News & Updates

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.

Autoimmune hepatitis (AIH), a chronic inflammatory liver disease, appears to increase the 10-year risk of cancer by 1.5-fold relative to age- and sex-matched controls, a study has shown.

A rehabilitation programme comprising intensive perioperative pulmonary rehabilitation (PR) and standard of care (SC) led to improved exercise capacity and tolerance in individuals with early-stage non-small-cell lung cancer (NSCLC) who are undergoing lung resection, the PUREAIR trial suggests.

Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

Use of 5α-reductase inhibitors (5ARIs) appears to lower the risk of community-acquired infection with SARS-CoV-2 in men without prostate cancer, according to a study, noting that treatment with this drug class can help ease the burden of COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic has led to a sharp decline in treatment for older patients with newly diagnosed cancers of the digestive system, a recent study has found.